Gebro Pharma joins the International Brain Tumour Day to raise awareness

The Spanish Association of People Affected by Brain Tumours (ASATE); the DACER Foundation, specialized in rehabilitation of brain damage; the Hospital Universitario Ramón y Cajal in Madrid, in collaboration with Laboratorios Gebro Pharma have held a conference this morning because of International Brain Tumour Day with the aim of informing and raising awareness of this pathology and the situation and needs of patients and their families.  

Each year 3,500 new cases of brain tumour are diagnosed and it’s the second cause of cancer in children aged 0-5; in the case of brain metastasis the figure rises to 14,000 cases.

More specifically, the incidence of this type of cancer is of 7.5 cases within a population of 100,000, approximately 2% being oncologic processes in adults and around 15% in children and young people.

During the event, the head of the Neurosurgery Service at the Hospital Universitario Ramón y Cajal, Dr. Luis Ley Urzaiz, has explained the great progress made in this field in the last 30 years. “Surgery is the pillar of glioma treatment and it’s been demonstrated that full surgical resection is the best option, since a resection of over 90% of the tumour can double the chance of survival of these patients”.

Dr. Ley has also commented on “the great effort made by all the parties involved, from doctors, hospitals and also the pharmaceutical industry, to improve the quality of life of patients affected by these rare tumours”.

Oscar Prieto, president of ASATE, has highlighted “the importance of rehabilitation that most patients needs after the treatments”, a service not available in all hospitals. The association also organizes charity events like padel tennis tournaments next July 19th in Madrid or the Charity Race on September 27th in the Parque Juan Carlos in Madrid to help the patients.

Finally, during the conference and for the first time in Spain, a simulation has been carried out on the specialized rehabilitation of brain damage and the patients’ needs for a better quality of life.